Research and Clinical Trials

Brief Description Principal Investigator
The primary objective of this study is to evaluate safety and tolerability and select a recommended Phase 2 dose (RP2D) of ADXS31-164 in subjects with solid tumors that express HER2 Tan, Antoinette Roslyn
To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug. Kim, Edward Sanghyun
To investigate the safety and tolerability of selumetinib when given in combination with MEDI4736 to patients with advanced solid malignancies. Kim, Edward Sanghyun
To assess the efficacy of MEDI4736 + tremelimumab combination therapy compared
to SoC in terms of PFS in patients with NSCLC.
Carrizosa, Daniel Ricardo
The primary objective of this trial is to establish statistical equivalence in terms of efficacy (overall response rate (ORR), proportion of patients with Complete Response (CR) plus Partial Response (PR) until 18 weeks of first-line treatemnt with BI 695502 plus chemotherapy versus Avastin plus chmeotherapy, followed by maintenance therapy. Kim, Edward Sanghyun
The purpose of this study is to evaluate the objective response rate (ORR) of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic tumors. Amin, Asim
To evaluate progression free survival (PFS) with nab-paclitaxel as maintenance treatment after response or stable disease (SD) with nab-paclitaxel plus carboplatin in subjects with squamous cell NSCLC. Mileham, Kathryn Finch
To assess the safety and tolerability of weekly continous nab-paclitaxel (Abraxane®) vs. with 1 week break in combination with Carboplatin as 1st line treatment for advanced NSCLC in elderly subjects >70 years old). Haggstrom, Daniel Ernest
Celgene ABI-007-ST-001 Carrizosa, Daniel Ricardo
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.

II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.

III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
Kaplan, Joel Adam
The primary objective of this study is to evaluate the safety and tolerability of LY2835219 when administered orally in combination with multiple single-agent options to patients with Stage IV non-small cell lung cancer (NSCLC) using Common Terminology Criteria for Adverse Events (CTCAE version 4.0, NCI 2009). The secondary objectives of the study are to determine the pharmacokinetics (PK) of LY2835219 when given in combination with multiple single-agent options; to document the antitumor activ Kim, Edward Sanghyun
To assess the safety and tolerability of the combination of PEGPH20 with docetaxel (PDoc).
To determine the recommended Phase 2 dose (RP2D) of PDoc.
To determine the recommended Phase 2 schedule of PDoc in subjects whose tumors have high levels of HA (high-HA).
Haggstrom, Daniel Ernest
Primary:
To assess the response rate of the combination of carboplatin and abraxane in patients with advanced non-small cell lung cancer (NSCLC).
Secondary:
To assess the disease control rate, duration of response, duration of disease control, overall survival, progression-free survival, and the safety and toxicity profile with this regimen.
Exploratory:
To assess broad molecular profiling.
Mileham, Kathryn Finch
Part A Objective:
The primary objective of Part A is to assess the safety and tolerability of ramucirumab when administered in
combination with erlotinib as therapy in previously untreated patients with EGFR mutation-positive metastatic
NSCLC.
Part B:
Primary Objectives:
The primary objective of Part B is to compare PFS of ramucirumab administered in combination with erlotinib versus
placebo in combination with erlotinib as therapy in previously untreated patients with EGFR mutation-posit
Mileham, Kathryn Finch
This registry is intended to measure the effect of myPlan Lung Cancer? test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC.

Mileham, Kathryn Finch
To assess 6 month PFS rate of Nivolumab in combination with EGF816 in EGFR mutated NSCLC patients and of Nivolumab in combination with
INC280 in patients with cMET positive NSCLC patients
Mileham, Kathryn Finch
Close